Tag: Dana-Farber Cancer Institute
-
Nation & World
Finding ovarian cancer’s vulnerabilities
In their largest and most comprehensive effort to date, researchers from the Broad Institute of Harvard and MIT and Dana-Farber Cancer Institute, a Harvard affiliate, examined cells from more than 100 tumors, including 25 ovarian cancer tumors, to unearth the genes upon which cancers depend. They call it Project Achilles.
-
Nation & World
When estrogen isn’t the culprit
Although it sounds like a case of gender confusion on a molecular scale, the male hormone androgen spurs the growth of some breast tumors in women. In a new study, Harvard scientists at Dana-Farber Cancer Institute provide the first details of the cancer cell machinery that carries out the hormone’s relentless growth orders.
-
Nation & World
Come on, Eileen
Workers at Harvard’s Biological Laboratories organize a team to raise funds for cancer research, and to support ill colleague Eileen Snow.
-
Nation & World
What’s behind aggressive breast cancer
Harvard scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.
-
Nation & World
Cancer cells’ survival kit
Harvard-affiliated scientists at Dana-Farber Cancer Institute have discovered new details of how cancer cells escape from tumor suppression mechanisms that normally prevent these damaged cells from multiplying.
-
Nation & World
Better blood
An innovative experimental treatment for boosting the effectiveness of blood stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, according to Harvard Stem Cell Institute scientists at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Children’s Hospital Boston.
-
Nation & World
The improbable appears promising
A section of the AIDS virus’ protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Harvard-affiliated Dana-Farber Cancer Institute scientists indicates.
-
Nation & World
Harvard rallies against cancer
Now through April 8, team up with other Harvard faculty and staff members to shut out cancer through Harvard Community Gifts.
-
Nation & World
Multiple myeloma genome unveiled
Harvard scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer.
-
Nation & World
Dilemmas of destiny
As genetic testing and its offspring — personalized medicine — have matured, patients and doctors have become entangled in such issues as how to best share at-risk information, access treatment options, and weigh decisions about threats to the young and unborn. And sometimes these issues mushroom, becoming quandaries for society as a whole.
-
Nation & World
Genes tied to prostate cancer uncovered
For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease.
-
Nation & World
Partial reversal of aging achieved in mice
Harvard scientists at Dana-Farber Cancer Institute say they have for the first time partially reversed age-related degeneration in mice, resulting in new growth of the brain and testes, improved fertility, and the return of a lost cognitive function.
-
Nation & World
Critical finding for skin cancer treatment
Researchers’ findings pinpoint a critical gene involved in melanoma growth, and provide a framework for discovering ways to tackle cancer drug resistance.
-
Nation & World
Challenge of finding a cure
A large, multidisciplinary panel has recently selected 12 pioneering ideas for attacking type 1 diabetes, ideas selected through a crowdsourcing experiment called the “Challenge,” in which all members of the Harvard community, as well as members of the general public, were invited to answer the question: What do we not know to cure type 1…
-
Nation & World
Poised for progress
A discovery by scientists at Harvard-affiliated Dana-Farber Cancer Institute may lead to an effective way of operating the immune system’s internal “control panel,” improving therapies for a variety of diseases.
-
Nation & World
Zon, Scadden recognized by American Society of Hematology
Two Harvard faculty members and members of the Harvard Stem Cell Institute, David Scadden and Leonard Zon, have won awards from the American Society of Hematology for contributions to understanding and treating blood diseases.
-
Nation & World
Better odds
Test could predict which children with T-cell acute lymphoblastic leukemia are best candidates for clinical trials of new therapies, research finds.
-
Nation & World
Six Harvard affiliates receive Damon Runyon fellowships
Six Harvard affiliates have been named recipients of fellowships by the Damon Runyon Cancer Research Foundation, a nonprofit organization focused on supporting exceptional early-career researchers and innovative cancer research.
-
Nation & World
From the cosmos to the cell
A conference at the Radcliffe Institute for Advanced Study examined the prevalence of patterns in the natural world, from enormous ones that order the cosmos to cellular and molecular patterns in living things.
-
Nation & World
Evening with Champions
With her spotlight purring like an old projector, Linda Yao ’10 used a steady hand to follow the cast of famed figure skaters as they shaved graceful ribbons into the ice during “An Evening with Champions.”
-
Nation & World
Kaelin among Canada Gairdner Award recipients
William Kaelin, a physician-scientist at Dana-Farber Cancer Institute, has been named one of seven recipients of the 2010 Canada Gairdner Award.
-
Nation & World
Childhood cancer survivors may face shortened lifespan, study reveals
Although more children today are surviving cancer than ever before, young patients successfully treated in the 1970s and 80s may live a decade less, on average, than the general population,…